For decades, the cardiovascular case for cacao was built on mechanism. Flavanols stimulate nitric oxide production. Nitric oxide dilates blood vessels. Dilated vessels reduce blood pressure. Lower blood pressure reduces cardiac events. The logic was sound. The clinical evidence — at scale — was missing.
In 2022, that changed. The COcoa Supplement and Multivitamin Outcomes Study (COSMOS), led by Dr. Howard Sesso and Dr. JoAnn Manson at Harvard Medical School and Brigham and Women's Hospital, published its primary results. 21,442 US adults — 12,666 women aged ≥65 and 8,776 men aged ≥60 — were randomly assigned to 500 mg/day of cocoa flavanols or a placebo. The trial ran for a median of 3.6 years. It was randomized, double-blind, and placebo-controlled — the gold standard of clinical evidence.
"Cocoa extract supplementation did not significantly reduce total cardiovascular events among older adults but reduced CVD death by 27%. Potential reductions in total cardiovascular events were supported in per-protocol analyses."
The primary outcome — total cardiovascular events — showed a hazard ratio of 0.90 (95% CI: 0.78–1.02). Trending toward benefit, but not statistically significant by conventional thresholds in the full intention-to-treat analysis. This is the number critics sometimes cite.
The secondary outcome — cardiovascular death specifically — showed a hazard ratio of 0.73 (95% CI: 0.54–0.98). That is a 27% reduction in the chance of dying from a cardiovascular event. Statistically significant. P = 0.04. The confidence interval does not cross 1.0.
In per-protocol analyses, which examined participants who consistently took their supplements, the primary outcome of total cardiovascular events also crossed into significance (HR: 0.85; 95% CI: 0.72–0.99).
Cocoa flavanols — principally the monomers (−)-epicatechin and (+)-catechin, and the procyanidins dimers B1 and B2 — activate endothelial nitric oxide synthase (eNOS) in the cells lining blood vessels. The resulting nitric oxide causes smooth muscle cells in vessel walls to relax. The vessels widen. Blood flows more easily. Systemic vascular resistance drops.
This is vasodilation. And it is the opposite of what caffeine does. Caffeine is a vasoconstrictor. It narrows vessels. It raises systolic blood pressure by an average of 8 mmHg in acute exposure. Over time, the cardiovascular load of daily vasoconstriction is measurable.
Flavanols also inhibit platelet aggregation — reducing the tendency of blood to clot — and decrease LDL oxidation, which is the process that converts LDL cholesterol into the form that damages artery walls. The multi-pathway nature of flavanol action is one reason the cardiovascular signal in COSMOS appeared even in a 3.6-year follow-up window.
A separate line of evidence published in the BMJ in 2024 added another dimension to the cardiovascular picture. Researchers at Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital analyzed data from three large prospective cohort studies: the Nurses' Health Study (1986–2018), Nurses' Health Study II (1991–2021), and the Health Professionals Follow-Up Study (1986–2020). Total participants: 192,208.
The key distinction was between chocolate subtypes. Dark chocolate and milk chocolate are not equivalent — they differ substantially in cocoa content, flavanol concentration, and the presence of milk proteins that may interfere with flavanol absorption.
Among those consuming ≥5 servings/week of dark chocolate, the multivariable-adjusted hazard ratio for type 2 diabetes was 0.79 (95% CI: 0.66–0.95) — a 21% lower risk compared to those who rarely consumed dark chocolate. The association was linear: each additional serving per week of dark chocolate was associated with a 3% reduction in T2D risk (P for linearity = 0.003). Milk chocolate showed no protective association.
The BMJ finding separates dark from milk chocolate because cocoa content predicts flavanol content — but only when the cocoa has been minimally processed. The Dutch-processing method, used in the majority of commercial cocoa products, treats cocoa with an alkalizing agent to reduce bitterness and darken color. The result is a smoother, more palatable product with up to 90% fewer flavanols than the raw bean.
This is not a minor distinction. The 500 mg dose tested in COSMOS is achievable from minimally processed, high-flavanol cacao. It is not achievable from most commercial cocoa products, hot chocolate mixes, or milk chocolate. The dose-response relationship is real. The source determines the dose.
Single-origin cacao, processed with preservation of the bean's bioactive compounds — fermented, not alkalized — delivers what the research tested. Everything else is a different product wearing the same name.